(Adds details on adverse events from report, background)

Feb 19 (Reuters) - The two COVID-19 vaccines approved foruse in the United States have reassuring safety profiles with noconcerning new issues found in data collected from the firstmonth of vaccinations, the U.S. Centers for Disease Control andPrevention (CDC) said on Friday.

After administration of 13.8 million doses of the Pfizer/BioNTech and Moderna Inc vaccines tothe U.S. population, most reports indicated non-serious sideeffects of the type that had been expected, such as headachesand fatigue. No deaths have been attributed to the vaccines, thedata showed.

The CDC collected data between Dec. 14, 2020 and Jan. 13,2021 from both an existing national surveillance system foradverse events and its own safety monitoring system establishedfor COVID-19 vaccines.

During that time, 6,994 reports of adverse events aftervaccination were recorded in the national surveillance systemwith 90.8% of them classified as non-serious and 9.2% asserious.

Rare cases of anaphylaxis, a severe allergic reactionrequiring medical attention, were reported with both vaccines ata rate of 4.5 cases per million doses administered, down fromthe agency's previously reported rate of 5 per million dosesadministered.

"Healthcare providers and vaccine recipients can bereassured about the safety of Pfizer and Moderna COVID-19vaccines," the CDC said in its Morbidity and Mortality WeeklyReport.

A total of 113 deaths were reported and availableinformation, including from death certificates and autopsyreports, found no causal link between COVID-19 vaccination andfatalities, CDC said.(Reporting by Vishwadha Chander in Bengaluru; Editing byCaroline Humer and Bill Berkrot)